Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Novartis Refocuses Shanghai Research Institute on Drug Development, not Discovery

publication date: Nov 18, 2019

Novartis plans big changes to its large Shanghai research institute, refocusing the facility on drug development rather than drug discovery. According to a company official, the China facility has been successful at discovering drug candidates, but after "China's explosion of talent," Novartis needs development services, for molecules discovered both in and out of China. The company plans to file 50 new drug applications in China, and it will also strengthen its business development team as it builds relationships with young China biopharmas. More details....

Stock Symbol: (NYSE: NVS)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.